| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | New Constructs, LLC |
N/A
| DYAX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 30-Nov-2009 | Pechala's Reports | Lubomir Pechala | DYAX CORP (DYAX=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for DYAX | 13 |
$25 |
| 29-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: DYAX CORP | 5 |
$25 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Dyax Corp | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | DYAX CP (DYAX=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | DYAX CP (DYAX=US) 2-weeks forecast | 1 |
$10 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: DYAX CORP -- DYAX | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AKRX , AOB , AUXL , AVNR , DYAX , IPXL , SCLN , SCMP -- DRUGS | 3 |
$4 |
0.52% Nasdaq 
0.05 (1.23%) 
Research Reports
